New survey findings presented at ICS shows 82% of participating patients with Urgency Urinary Incontinence (UUI) experience leakage once a week or more.
Data presented at ICS demonstrates maintained quality of life improvements in elderly patients with OAB at 24 weeks with Toviaz (fesoterodine).
Findings from a new European survey, announced at the International Continence Society (ICS) annual meeting in Glasgow, show that 82% of surveyed patients with overactive bladder (OAB) who have urgency urinary continence (UUI) experience leakage once a week or more.
These patients report that they find leakage to be the most bothersome symptom of their OAB.
Data presented at ICS also show that improvements in quality of life (QoL) for elderly patients were maintained at 24 weeks of treatment with Toviaz (fesoterodine).
The European survey findings show that 53% of patients with OAB who have UUI report a significant impact on quality of life compared with 42% of OAB patients without UUI.
The survey also highlighted that OAB symptoms have a greater negative impact on daily life for UUI patients than for OAB patients without UUI, including the impact on enjoying activities outside the home (51% vs. 34%) and on their self-esteem (40% vs. 22%).
The survey, carried out across six countries with more than 1000 patients taking part, was sponsored by Pfizer.
Mr Marcus Drake, Consultant Urological Surgeon, Bristol Urological Institute, Bristol, UK who was involved in developing the survey said, “Although we have seen clinical evidence to show the impact of urinary incontinence on patient quality of life, it is moving to hear from the patients themselves how stressful and limiting this condition is on their everyday functioning. This survey highlights to all of us, particularly the physicians, how important it is to work with patients to agree their treatment goals and manage their treatment expectations. Working together we can ensure that we improve their quality of life.”
Existing data shows that fesoterodine improves QoL in the elderly. At 12 weeks elderly OAB patients who had received fesoterodine (4mg and 8mg) had greater improvement in quality of life compared with those patients receiving placebo.
New data presented at ICS shows that in an open-label phase of the study, patients who remained on fesoterodine up to 24 weeks maintained those improvements. This study also demonstrates that 24 weeks of fesoterodine treatment is generally well-tolerated in an elderly population.
Dr Daniela Marshall-Kehrel, head doctor at a private urological office in Frankfurt, Germany said “OAB has a great impact on patients’ quality of life, even more so for those patients who have UUI. There are treatments available that can improve patient QoL and the new data shows evidence that fesoterodine can deliver this. It is important that patients adhere to their medication so that the benefits in quality of life can be maintained. Physicians have a key role to play in supporting patients through treatment to achieve their goals for quality of life improvement.”